Evidence map›Paper›PMID 28197292›Full record

ArticleCardiology research2016

Chlorthalidone Plus Amiloride Reduces the Central Systolic Blood Pressure in Stage 1 Hypertension Patients.

Leticia Aparecida Barufi Fernandes, Elizabeth do Espirito Santo Cestario, Luciana Neves Cosenso-Martin, Jose Fernando Vilela-Martin, Juan Carlos Yugar-Toledo, Flavio Danni Fuchs

Open access · diamondAbstract read
In one paragraph

Article in Cardiology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Do thiazide diuretics reduce central systolic blood pressure in hypertension?Journal of clinical hypertension (Greenwich, Conn.) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Leticia Aparecida Barufi FernandesHypertension Clinic, Department of Internal Medicine, State Medical School of Sao Jose do Rio Preto (FAMERP), Sao Paulo, Brazil.
Elizabeth do Espirito Santo CestarioHypertension Clinic, Department of Internal Medicine, State Medical School of Sao Jose do Rio Preto (FAMERP), Sao Paulo, Brazil.
Luciana Neves Cosenso-MartinEndocrinology Division of the Internal Medicine Department, State Medical School of Sao Jose Rio Preto, SP (FAMERP), Brazil.
Jose Fernando Vilela-MartinHypertension Clinic, Department of Internal Medicine, State Medical School of Sao Jose do Rio Preto (FAMERP), Sao Paulo, Brazil.
Juan Carlos Yugar-ToledoHypertension Clinic, Department of Internal Medicine, State Medical School of Sao Jose do Rio Preto (FAMERP), Sao Paulo, Brazil.
Flavio Danni FuchsDivision of Cardiology, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Faculdade de Medicina de São José do Rio Preto · BRHospital de Clínicas de Porto Alegre · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure. Related clinical implications suggest that individuals with normal peripheral but high central blood pressure should not receive antihypertensive drugs that act on the central pressure. Therefore, they are at greater cardiovascular risk. The aim of the study was to evaluate the effect of treatment with a thiazide diuretic versus losartan on the central blood pressure in stage 1 hypertensive patients.

methodsTwenty-five patients were randomized to the chlorthalidone 25 mg/amiloride 5 mg group (q.d.) and 25 patients received losartan 50 mg (b.i.d). The central systolic blood pressure (CSBP) and augmentation index (AIx 75) were assessed using applanation tonometry. The paired

resultsSignificant reductions in CSBP (123.3 ± 14.2 vs. 113.4 ± 111.4, P = 0.0103) and AIx 75 (87.7 ± 9.6 vs. 83.8 ± 8.9, P = 0.0289) were observed after 6 months of drug treatment with chlorthalidone 25 mg/amiloride 5 mg (q.d.). The administration of losartan 50 mg (b.i.d) did not reduce the CSBP and there were insignificant changes in the AIx 75.

conclusionsSix-month treatment of chlorthalidone/amiloride but not losartan reduces the CSBP and AIx 75 in adults with stage 1 hypertension.

Indexed as

AmilorideCentral systolic blood pressureChlorthalidoneLosartanStage 1 hypertension

Identifiers

PMID28197292
PMCPMC5295510
OpenAlexW2562514678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.